Omidenepag isopropyl is converted to the active product Omidenepag during corneal penetration. Omidenepag isopropyl is a selective EP2 receptor agonist. Omidenepag isopropyl displays only a weak affinity for EP1, EP2, and FP receptors. Omidenepag isopropy

Omidenepag isopropyl, when hydrolyzed in the eye, becomes Omidenepag (OMD), an EP2 receptor agonist demonstrating a pronounced ocular hypotensive effect across both normotensive and hypertensive animal models[1]. This compound has shown significant, dose-dependent intraocular pressure (IOP) reduction in normotensive monkeys at concentrations of 0.0001%, 0.001%, and 0.01%, achieving mean maximal IOP reductions of 2.4 ± 0.6, 7.6 ± 1.7, and 13.3 ± 1.2 mm Hg, respectively. In a study, either Omidenepag isopropyl, Xalatan, or a vehicle was administered topically to one eye of normotensive monkeys, with the alterations in IOP measured against a predosing baseline from day 1. Notably, for concentrations of 0.001% and 0.01%, significant reductions in IOP were observed at the outset of day 7. Moreover, in hypertensive monkeys, Omidenepag isopropyl was found to lower IOP by enhancing both trabecular and uveoscleral outflow[2].